DoD Melanoma, Team Science Award

archived

The FY19 MRP Team Science Award (TSA) supports hypothesis-driven studies across the entire spectrum of research to tackle the overarching FY19 MRP Challenge Statement and FY19 MRP Focus Areas. The TSA is intended to advance studies in melanoma through a multidisciplinary team, bringing together divergent disciplines to foster a novel approach to melanoma research. The TSA requires that investigators jointly design a single project. However, each partner will be recognized as a Principal Investigator (PI), must submit a separate application, and will be the named PI on an individual award. The application must clearly define the synergistic components that will facilitate and accelerate progress in melanoma in a way that could not be accomplished through independent efforts. Each team member should offer unique skill sets and offer different perspectives on the project. Research projects funded by the TSA should address critical knowledge gaps with the FY19 MRP Challenge Statement covering at least one of the required FY19 MRP Focus Areas. The Team Science Award is not intended to study research into established late-stage disease models or the clinical utility of PD-1 in combination with other therapeutics. Studies involving non-melanoma skin cancers are not allowed under the FY19 MRP. Funding for clinical trials is not allowed. The TSA may support studies in animal models, human subjects, and human anatomical substances. Accordingly, development or use of relevant preclinical models may be included. The TSA is not intended to support high-throughput screenings, sequencing, etc.

High